Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-DTPA-hIgG
- Development stage
- Preclinical
- Lead developer
- Institute of Materia Medica, Chinese Academy of Medical Sciences
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[177Lu]Lu-DTPA-hIgG is a radiolabeled non-specific human immunoglobulin G (hIgG) conjugate. It consists of human IgG antibodies conjugated to the chelator diethylenetriaminepentaacetic acid (DTPA) and labeled with the beta-emitting radioisotope lutetium-177 (177Lu). In the context of oncology research, specifically in studies of acute myeloid leukemia (AML), it is utilized as a non-targeted control radiopharmaceutical to assess the background radiation effects and the specific targeting efficiency of other radioimmunotherapy agents, such as CD123-targeted [177Lu]Lu-DTPA-pivekimab. It helps distinguish between the therapeutic effects of targeted radiation versus non-specific systemic radiation.
- Other names
- 177Lu-DTPA-hIgGLutetium-177 labeled human IgGLutetium177 labeled human IgGLutetium 177 labeled human IgG
02
Targets
FCGRT (Neonatal crystallizable fragment receptor)DNAFcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on [177Lu]Lu-DTPA-hIgG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [177Lu]Lu-DTPA-hIgG.